Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
BUSINESS
AnGes Seeks Full Approval for Gene Therapy Collategene in Japan
Osaka-based biotech AnGes said on May 31 that it has filed an application seeking full Japanese regulatory approval for its HGF gene therapy Collategene (beperminogene perplasmid), which had been granted conditional, time-limited approval in 2019. In March 2019, Collategene was…
To read the full story
Related Article
- Payer Chides AnGes’s Course Change on Collategene, Urges Re-Think of System’s Set-Up
July 4, 2024
- AnGes Alters Strategy for Collategene, Halts Japan Sales for Fresh Submission
June 25, 2024
- AnGes Calls off Japan Development of Collategene for Additional Indication
September 8, 2022
- Collategene Generates Only 4 Million Yen in 4 Months
February 5, 2020
- Full Approval in Japan Will Be 1st Goal for Collategene: AnGes Chief
September 11, 2019
- Anges, Mitsubishi Tanabe to Launch Gene Therapy Collategene on Sept. 10
September 5, 2019
- Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
August 28, 2019
- After Listing Delayed, Collategene Expected to Reach Market by Year-End: AnGes Founder
July 22, 2019
- AnGes Delays Launch of Collategene, “Sale Preparations Will Take More Time”
May 15, 2019
- AnGes Bags Conditional Approval for Collategene Gene Therapy
March 27, 2019
- MHLW Panel OKs AnGes’ Gene Therapy Collategene for Conditional Approval
February 21, 2019
BUSINESS
- Nihon Servier Files Glioma Drug Vorasidenib in Japan
December 25, 2024
- Sumitomo’s Gemtesa Expands Label in US to OAB Patients with BPH
December 25, 2024
- Daiichi, AZ Pull EU Dato-DXd Filing for Lung Cancer
December 25, 2024
- Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
- Increased Off-Year Pressure on LLPs Would Only Exacerbate Supply Crunch: Industry Officials
December 24, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…